Gamco Investors INC. ET AL increased its holdings in Amgen, Inc. (NASDAQ:AMGN) by 20.5% in the 3rd quarter, according to the company in its most recent filing with the Securities and Exchange Commission (SEC). The institutional investor owned 7,286 shares of the medical research company’s stock after acquiring an additional 1,242 shares during the quarter. Gamco Investors INC. ET AL’s holdings in Amgen were worth $1,410,000 as of its most recent filing with the Securities and Exchange Commission (SEC).

Other large investors have also recently added to or reduced their stakes in the company. Advisors Preferred LLC bought a new stake in Amgen during the 2nd quarter valued at about $30,000. Arbor Wealth Management LLC increased its stake in Amgen by 154.5% during the 2nd quarter. Arbor Wealth Management LLC now owns 168 shares of the medical research company’s stock valued at $31,000 after purchasing an additional 102 shares in the last quarter. Atwater Malick LLC bought a new stake in Amgen during the 3rd quarter valued at about $39,000. Ashburton Jersey Ltd bought a new stake in Amgen during the 2nd quarter valued at about $42,000. Finally, Sound Income Strategies LLC increased its stake in Amgen by 402.1% during the 2nd quarter. Sound Income Strategies LLC now owns 236 shares of the medical research company’s stock valued at $43,000 after purchasing an additional 189 shares in the last quarter. Institutional investors and hedge funds own 76.33% of the company’s stock.

In other news, SVP Cynthia M. Patton sold 13,426 shares of Amgen stock in a transaction that occurred on Friday, August 30th. The shares were sold at an average price of $208.07, for a total transaction of $2,793,547.82. Following the sale, the senior vice president now owns 32,648 shares in the company, valued at $6,793,069.36. The transaction was disclosed in a document filed with the SEC, which is available at this link. Also, Director R Sanders Williams sold 425 shares of the business’s stock in a transaction on Wednesday, November 6th. The stock was sold at an average price of $215.45, for a total transaction of $91,566.25. Following the completion of the sale, the director now owns 5,413 shares in the company, valued at approximately $1,166,230.85. The disclosure for this sale can be found here. In the last quarter, insiders have sold 17,851 shares of company stock worth $3,685,674. Company insiders own 0.25% of the company’s stock.

A number of analysts have weighed in on AMGN shares. Mizuho restated a “hold” rating and set a $212.00 price objective on shares of Amgen in a research note on Sunday, September 29th. Leerink Swann raised their price target on shares of Amgen from $189.00 to $205.00 and gave the company a “market perform” rating in a report on Wednesday, October 30th. Sanford C. Bernstein assumed coverage on shares of Amgen in a report on Monday, October 14th. They set an “outperform” rating on the stock. Evercore ISI reaffirmed a “hold” rating on shares of Amgen in a report on Sunday, August 11th. Finally, Morgan Stanley dropped their price target on shares of Amgen from $211.00 to $207.00 and set an “overweight” rating on the stock in a report on Monday, July 15th. Ten equities research analysts have rated the stock with a hold rating and twelve have assigned a buy rating to the company. Amgen has an average rating of “Buy” and an average price target of $219.56.

Shares of AMGN traded up $3.12 on Friday, reaching $221.11. The company’s stock had a trading volume of 2,069,900 shares, compared to its average volume of 2,911,719. The stock has a market capitalization of $127.80 billion, a P/E ratio of 15.35, a PEG ratio of 2.21 and a beta of 1.09. The company has a debt-to-equity ratio of 2.54, a current ratio of 2.89 and a quick ratio of 2.59. Amgen, Inc. has a 12-month low of $166.30 and a 12-month high of $221.25. The stock’s 50 day simple moving average is $202.75 and its two-hundred day simple moving average is $188.90.

Amgen (NASDAQ:AMGN) last released its quarterly earnings data on Tuesday, October 29th. The medical research company reported $3.66 earnings per share (EPS) for the quarter, beating the consensus estimate of $3.53 by $0.13. The firm had revenue of $5.74 billion for the quarter, compared to analysts’ expectations of $5.63 billion. Amgen had a net margin of 34.48% and a return on equity of 80.26%. The company’s revenue for the quarter was down 2.8% compared to the same quarter last year. During the same quarter last year, the business posted $3.69 earnings per share. Analysts expect that Amgen, Inc. will post 14.44 earnings per share for the current year.

The business also recently disclosed a quarterly dividend, which will be paid on Friday, December 6th. Stockholders of record on Friday, November 15th will be given a dividend of $1.45 per share. This represents a $5.80 annualized dividend and a dividend yield of 2.62%. The ex-dividend date is Thursday, November 14th. Amgen’s payout ratio is currently 40.28%.

Amgen Company Profile

Amgen Inc discovers, develops, manufactures, and delivers human therapeutics worldwide. It offers products for the treatment of oncology/hematology, cardiovascular, inflammation, bone health, and neuroscience. The company's products include Enbrel to treat plaque psoriasis, rheumatoid arthritis, and psoriatic arthritis; Neulasta, a pegylated protein to treat cancer patients; Prolia to treat postmenopausal women with osteoporosis; Aranesp to treat anemia; Xgeva for skeletal-related events prevention; Sensipar/Mimpara products to treat sHPT in chronic kidney disease; and EPOGEN to treat a lower-than-normal number of red blood cells.

Recommended Story: How to Track your Portfolio in Google Finance

Want to see what other hedge funds are holding AMGN? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Amgen, Inc. (NASDAQ:AMGN).

Institutional Ownership by Quarter for Amgen (NASDAQ:AMGN)

Receive News & Ratings for Amgen Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Amgen and related companies with MarketBeat.com's FREE daily email newsletter.